Light-activatable dual-source ROS-responsive prodrug nanoplatform for synergistic chemo-photodynamic therapy-Reference-Cited by-同舟云学术

Light-activatable dual-source ROS-responsive prodrug nanoplatform for synergistic chemo-photodynamic therapy

Published:2018 Issue:11 Volume:6 Page:2965-2975
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Yang Bin¹²³⁴⁵,Wang Kaiyuan¹²³⁴⁵,Zhang Dong¹²³⁴⁵,Sun Bingjun¹²³⁴⁵,Ji Bin⁶⁷⁸⁴⁵,Wei Lin⁹¹⁰¹¹¹²⁵,Li Zhenbao¹²³⁴⁵,Wang Menglin¹²³⁴⁵,Zhang Xuanbo¹²³⁴⁵,Zhang Haotian¹³³¹⁴⁵,Kan Qiming¹³³¹⁴⁵,Luo Cong¹²³⁴⁵,Wang Yongjun¹²³⁴⁵,He Zhonggui¹²³⁴⁵,Sun Jin¹²³⁴⁵^ORCID

Affiliation:

1. Department of Pharmaceutics

2. Wuya College of Innovation

3. Shenyang Pharmaceutical University

4. Shenyang

5. China

6. Department of Laboratory Medicine

7. The First Affiliated Hospital

8. China Medical University

9. Key Laboratory of Microbiology

10. School of Life Science

11. Heilongjiang University

12. Harbin

13. School of Life Science and Biopharmaceutics

14. Shenyang 110016

Abstract

In the context of prodrug nanomedicines for cancer therapy, one of the great challenges is the slow and variable release of the parent drug in tumors.

Funder

National Natural Science Foundation of China

China Postdoctoral Science Foundation

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2018/BM/C8BM00899J

Reference35 articles.

1. Prodrug-based intracellular delivery of anticancer agents

2. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy